---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-029741"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2021-11-24T23:59:59+00:00"
generated_at: "2026-06-28T05:38:28.020401+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Oncotelic reports positive Phase 2 COVID-19 data: 3X survival benefit for critical patients

## Summary
- Safety endpoints met; OT-101 was safe in severe/critical COVID-19 patients.
- End-of-treatment mortality: 4.5% OT-101 vs 20% placebo.
- Viral load knockdown >96% in 89% of OT-101 patients vs 67% placebo.
- Overall survival for critical patients: 14 days OT-101 vs 4 days placebo (p<0.0166).

## SEC filing metadata
- accession: 0001493152-21-029741
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2021-11-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315221029741/0001493152-21-029741-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315221029741/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-029741
- JSON: https://secwatch.observer/filing/0001493152-21-029741.json
- Plain text: https://secwatch.observer/filing/0001493152-21-029741.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.